Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis

Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis Primary myelofibrosis (PMF) is one of the BCR/ABL-negative myeloproliferative neoplasms (MPNs), characterized by the diffuse fibrous hyperproliferation, bone marrow osteosclerosis, extramedullary hematopoiesis, and marked splenomegaly. The patients with PMF have an insidious onset, a long duration of clinical course, and the deteriorated quality of life. It has been reported that the CALR gene 9 exon mutations were detected in 25–30% PMF patients, particularly as high as 80% in the JAK2/MPL-negative ones. As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF. Moreover, the CALR mutations indicated a favorable prognosis, which the mechanism is still under investigation. It was demonstrated that a characterized high expression of EZH2 and SUZ12 in CALR-mutated patients. Taking EZH2 as the research entry point, we initially discussed the mechanism that the CALR-positive patients with PMF exhibited a better prognosis in the current study. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Annals of Hematology Springer Journals

Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis

16 pages
Read Article

Loading next page...
 
/lp/springer_journal/elevated-expression-of-the-ezh2-gene-in-calr-mutated-patients-with-3WFbqHBmia
Publisher
Springer Berlin Heidelberg
Copyright
Copyright © 2018 by Springer-Verlag GmbH Germany, part of Springer Nature
Subject
Medicine & Public Health; Hematology; Oncology
ISSN
0939-5555
eISSN
1432-0584
D.O.I.
10.1007/s00277-018-3287-8
Publisher site
See Article on Publisher Site

Abstract

Primary myelofibrosis (PMF) is one of the BCR/ABL-negative myeloproliferative neoplasms (MPNs), characterized by the diffuse fibrous hyperproliferation, bone marrow osteosclerosis, extramedullary hematopoiesis, and marked splenomegaly. The patients with PMF have an insidious onset, a long duration of clinical course, and the deteriorated quality of life. It has been reported that the CALR gene 9 exon mutations were detected in 25–30% PMF patients, particularly as high as 80% in the JAK2/MPL-negative ones. As the second most common mutation in BCR/ABL-negative MPNs, CALR mutation has been included in the latest World Health Organization (WHO) classification criteria as one of the main diagnostic criteria for both essential thrombocythemia (ET) and PMF. Moreover, the CALR mutations indicated a favorable prognosis, which the mechanism is still under investigation. It was demonstrated that a characterized high expression of EZH2 and SUZ12 in CALR-mutated patients. Taking EZH2 as the research entry point, we initially discussed the mechanism that the CALR-positive patients with PMF exhibited a better prognosis in the current study.

Journal

Annals of Hematology – Springer Journals

Published: Mar 20, 2018

References

  • Primary myelofibrosis: 2017 update on diagnosis, risk-stratification, and management
    Tefferi, A
  • Update from the latest WHO classification of MPNs: a user's manual
    Passamonti, F; Maffioli, M
  • The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    Vardiman, JW; Thiele, J; Arber, DA; Brunning, RD; Borowitz, MJ; Porwit, A; Harris, NL; Beau, MM; Hellstrom-Lindberg, E; Tefferi, A; Bloomfield, CD
  • The dynamic international prognostic scoring system for myelofibrosis predicts outcomes after hematopoietic cell transplantation
    Scott, BL; Gooley, TA; Sorror, ML; Rezvani, AR; Linenberger, ML; Grim, J; Sandmaier, BM; Myerson, D; Chauncey, TR; Storb, R; Buxhofer-Ausch, V; Radich, JP; Appelbaum, FR; Deeg, HJ
  • Allogeneic transplantation for patients with advanced myelofibrosis: splenomegaly and high serum LDH are adverse risk factors for successful engraftment
    Gergis, U; Kuriakose, E; Shore, T; Mayer, S; Mark, T; Pearse, R; Schuster, M; Feldman, E; Roboz, G; Ritchie, E; Scandura, J; Wang, H; Zhou, XK; Silver, RT; Besien, K
  • A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
    Verstovsek, S; Mesa, RA; Gotlib, J; Levy, RS; Gupta, V; DiPersio, JF; Catalano, JV; Deininger, M; Miller, C; Silver, RT; Talpaz, M; Winton, EF; Harvey, JJ; Arcasoy, MO; Hexner, E; Lyons, RM; Paquette, R; Raza, A; Vaddi, K; Erickson-Viitanen, S; Koumenis, IL; Sun, W; Sandor, V; Kantarjian, HM
  • Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients
    Polverelli, N; Breccia, M; Benevolo, G; Martino, B; Tieghi, A; Latagliata, R; Sabattini, E; Riminucci, M; Godio, L; Catani, L; Nicolosi, M; Perricone, M; Sollazzo, D; Colafigli, G; Campana, A; Merli, F; Vitolo, U; Alimena, G; Martinelli, G; Lewis, RE; Vianelli, N; Cavo, M; Palandri, F
  • JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
    Harrison, C; Kiladjian, JJ; Al-Ali, HK; Gisslinger, H; Waltzman, R; Stalbovskaya, V; McQuitty, M; Hunter, DS; Levy, R; Knoops, L; Cervantes, F; Vannucchi, AM; Barbui, T; Barosi, G
  • Safety and efficacy of ruxolitinib in splanchnic vein thrombosis associated with myeloproliferative neoplasms
    Pieri, L; Paoli, C; Arena, U; Marra, F; Mori, F; Zucchini, M; Colagrande, S; Castellani, A; Masciulli, A; Rosti, V; Stefano, V; Betti, S; Finazzi, G; Ferrari, ML; Rumi, E; Ruggeri, M; Nichele, I; Guglielmelli, P; Fjerza, R; Mannarelli, C; Fanelli, T; Merli, L; Corbizi, FG; Massa, M; Cimino, G; Rambaldi, A; Barosi, G; Cazzola, M; Barbui, T; Vannucchi, AM
  • Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study
    Campbell, PJ; Scott, LM; Buck, G; Wheatley, K; East, CL; Marsden, JT; Duffy, A; Boyd, EM; Bench, AJ; Scott, MA; Vassiliou, GS; Milligan, DW; Smith, SR; Erber, WN; Bareford, D; Wilkins, BS; Reilly, JT; Harrison, CN; Green, AR
  • SomaticCALRMutations in Myeloproliferative Neoplasms with NonmutatedJAK2
    Nangalia, J; Massie, CE; Baxter, EJ; Nice, FL; Gundem, G; Wedge, DC; Avezov, E; Li, J; Kollmann, K; Kent, DG; Aziz, A; Godfrey, AL; Hinton, J; Martincorena, I; Loo, P; Jones, AV; Guglielmelli, P; Tarpey, P; Harding, HP; Fitzpatrick, JD; Goudie, CT; Ortmann, CA; Loughran, SJ; Raine, K; Jones, DR; Butler, AP; Teague, JW; O'Meara, S; McLaren, S; Bianchi, M; Silber, Y; Dimitropoulou, D; Bloxham, D; Mudie, L; Maddison, M; Robinson, B; Keohane, C; Maclean, C; Hill, K; Orchard, K; Tauro, S; Du, MQ; Greaves, M; Bowen, D; Huntly, BJ; Harrison, CN; Cross, NC; Ron, D; Vannucchi, AM; Papaemmanuil, E; Campbell, PJ; Green, AR
  • Somatic mutations of calreticulin in myeloproliferative neoplasms
    Klampfl, T; Gisslinger, H; Harutyunyan, AS; Nivarthi, H; Rumi, E; Milosevic, JD; Them, NC; Berg, T; Gisslinger, B; Pietra, D; Chen, D; Vladimer, GI; Bagienski, K; Milanesi, C; Casetti, IC; Sant'Antonio, E; Ferretti, V; Elena, C; Schischlik, F; Cleary, C; Six, M; Schalling, M; Schonegger, A; Bock, C; Malcovati, L; Pascutto, C; Superti-Furga, G; Cazzola, M; Kralovics, R
  • Clinical effect of driver mutations of JAK2, CALR, or MPL in primary myelofibrosis
    Rumi, E; Pietra, D; Pascutto, C; Guglielmelli, P; Martinez-Trillos, A; Casetti, I; Colomer, D; Pieri, L; Pratcorona, M; Rotunno, G; Sant'Antonio, E; Bellini, M; Cavalloni, C; Mannarelli, C; Milanesi, C; Boveri, E; Ferretti, V; Astori, C; Rosti, V; Cervantes, F; Barosi, G; Vannucchi, AM; Cazzola, M
  • Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis
    Barbui, T; Thiele, J; Vannucchi, AM; Tefferi, A
  • CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons
    Tefferi, A; Lasho, TL; Finke, CM; Knudson, RA; Ketterling, R; Hanson, CH; Maffioli, M; Caramazza, D; Passamonti, F; Pardanani, A
  • Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact
    Tefferi, A; Lasho, TL; Finke, C; Belachew, AA; Wassie, EA; Ketterling, RP; Hanson, CA; Pardanani, A
  • Improved survival of calreticulin-mutated patients compared with Janus kinase 2 in primary myelofibrosis: a meta-analysis
    Kourie, HR; Ameye, L; Paesmans, M; Bron, D
  • The critical roles of endoplasmic reticulum chaperones and unfolded protein response in tumorigenesis and anticancer therapies
    Luo, B; Lee, AS
  • Calreticulin signaling in health and disease
    Wang, WA; Groenendyk, J; Michalak, M
  • The mutation profile of JAK2 and CALR in Chinese Han patients with Philadelphia chromosome-negative myeloproliferative neoplasms
    Wu, Z; Zhang, X; Xu, X; Chen, Y; Hu, T; Kang, Z; Li, S; Wang, H; Liu, W; Ma, X; Guan, M
  • Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value
    Vannucchi, AM; Rotunno, G; Bartalucci, N; Raugei, G; Carrai, V; Balliu, M; Mannarelli, C; Pacilli, A; Calabresi, L; Fjerza, R; Pieri, L; Bosi, A; Manfredini, R; Guglielmelli, P
  • Calreticulin mutations in myeloproliferative neoplasms
    Lavi, N
  • Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations
    Andrikovics, H; Krahling, T; Balassa, K; Halm, G; Bors, A; Koszarska, M; Batai, A; Dolgos, J; Csomor, J; Egyed, M; Sipos, A; Remenyi, P; Tordai, A; Masszi, T
  • Integrated genomic analysis illustrates the central role of JAK-STAT pathway activation in myeloproliferative neoplasm pathogenesis
    Rampal, R; Al-Shahrour, F; Abdel-Wahab, O; Patel, JP; Brunel, JP; Mermel, CH; Bass, AJ; Pretz, J; Ahn, J; Hricik, T; Kilpivaara, O; Wadleigh, M; Busque, L; Gilliland, DG; Golub, TR; Ebert, BL; Levine, RL
  • The roles of EZH2 in cell lineage commitment
    Chou, RH; Yu, YL; Hung, MC
  • Role of the polycomb repressive complex 2 (PRC2) in transcriptional regulation and cancer
    Laugesen, A; Højfeldt, JW; Helin, K
  • Atg3 overexpression enhances bortezomib-induced cell death in SKM-1 cell
    Zhuang, L; Ma, Y; Wang, Q; Zhang, J; Zhu, C; Zhang, L; Xu, X
  • Multiple mechanisms deregulate EZH2 and histone H3 lysine 27 epigenetic changes in myeloid malignancies
    Khan, SN; Jankowska, AM; Mahfouz, R; Dunbar, AJ; Sugimoto, Y; Hosono, N; Hu, Z; Cheriyath, V; Vatolin, S; Przychodzen, B; Reu, FJ; Saunthararajah, Y; O'Keefe, C; Sekeres, MA; List, AF; Moliterno, AR; McDevitt, MA; Maciejewski, JP; Makishima, H
  • Multifaceted role of the polycomb-group gene EZH2 in hematological malignancies
    Sashida, G; Iwama, A
  • Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders
    Ernst, T; Chase, AJ; Score, J; Hidalgo-Curtis, CE; Bryant, C; Jones, AV; Waghorn, K; Zoi, K; Ross, FM; Reiter, A; Hochhaus, A; Drexler, HG; Duncombe, A; Cervantes, F; Oscier, D; Boultwood, J; Grand, FH; Cross, NC
  • Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms
    Score, J; Hidalgo-Curtis, C; Jones, AV; Winkelmann, N; Skinner, A; Ward, D; Zoi, K; Ernst, T; Stegelmann, F; Dohner, K; Chase, A; Cross, NC
  • Calreticulin-mutant proteins induce megakaryocytic signaling to transform hematopoietic cells and undergo accelerated degradation and Golgi-mediated secretion
    Han, L; Schubert, C; Kohler, J; Schemionek, M; Isfort, S; Brummendorf, TH; Koschmieder, S; Chatain, N
  • Activation of the thrombopoietin receptor by mutant calreticulin in CALR-mutant myeloproliferative neoplasms
    Araki, M; Yang, Y; Masubuchi, N; Hironaka, Y; Takei, H; Morishita, S; Mizukami, Y; Kan, S; Shirane, S; Edahiro, Y; Sunami, Y; Ohsaka, A; Komatsu, N
  • Calreticulin, a multi-process calcium-buffering chaperone of the endoplasmic reticulum
    Michalak, M; Groenendyk, J; Szabo, E; Gold, LI; Opas, M
  • Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism
    Garbati, MR; Welgan, CA; Landefeld, SH; Newell, LF; Agarwal, A; Dunlap, JB; Chourasia, TK; Lee, H; Elferich, J; Traer, E; Rattray, R; Cascio, MJ; Press, RD; Bagby, GC; Tyner, JW; Druker, BJ; Dao, KH
  • Structural and functional relationships between the lectin and arm domains of calreticulin
    Pocanschi, CL; Kozlov, G; Brockmeier, U; Brockmeier, A; Williams, DB; Gehring, K
  • Calreticulin gene mutations in myeloproliferative neoplasms without Janus kinase 2 mutations
    Sun, C; Zhang, S; Li, J
  • Calreticulin is a receptor for nuclear export
    Holaska, JM; Black, BE; Love, DC; Hanover, JA; Leszyk, J; Paschal, BM
  • Uncovering the roles of miRNAs and their relationship with androgen receptor in prostate cancer
    Chun Jiao, S; Huan, C; Chao Yang, X; Guo Mei, R
  • Celastrol induces autophagy by targeting AR/miR-101 in prostate cancer cells
    Guo, J; Huang, X; Wang, H; Yang, H
  • MicroRNAs as regulators of signal transduction in urological tumors
    Fendler, A; Stephan, C; Yousef, GM; Jung, K
  • Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes
    Takeshita, F; Patrawala, L; Osaki, M; Takahashi, RU; Yamamoto, Y; Kosaka, N; Kawamata, M; Kelnar, K; Bader, AG; Brown, D
  • Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer
    Mo, W; Zhang, J; Li, X; Meng, D; Gao, Y; Yang, S; Wan, X; Zhou, C; Guo, F; Huang, Y; Amente, S; Avvedimento, EV; Xie, Y; Li, Y
  • Prolonged Ezh2 depletion in glioblastoma causes a robust switch in cell fate resulting in tumor progression
    Vries, NA; Hulsman, D; Akhtar, W; Jong, J; Miles, DC; Blom, M; Tellingen, O; Jonkers, J; Lohuizen, M

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off

Sign up
for free
Start 14 day
Free Trial